OSE Immunotherapeutics is a biotechnology company led by immunologists focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases, and transplantation. OSE Immunotherapeutics SA is a biotechnology business that focuses on the development of immunotherapies for immune activation and modulation in immuno-oncology and autoimmune illnesses. Tedopi, OSE-172, OSE-703, FR104, and OSE-127 are among the company's products.
Effimune is a biotechnology company that conducts research and development of drugs for transplantation and immune-mediated diseases. Effimune targeting cells of the immune system to restore the balance between effector and regulatory mechanisms. Effimune was founded in 2017 and was headquartered in Nantes, France.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.